Soft Tissue Image by KA Imaging’s Reveal 35C Undercovers Mass Behind In-Dwelling Device
27.2.2023 10:05:00 EET | Business Wire | Press release
Manufacturer KA Imaging announced a study examining “single-exposure dual-energy radiography for the subtraction of in-dwelling devices in the soft tissue image” that made use of the Reveal 35C X-ray detector, powered by Spectral DR™ technology.
Using the Reveal 35C detector, the purpose of the study was to determine the clinical value of removal of in-dwelling devices in the dual-energy soft tissue X-ray image. According to the study, the spectral radiographic images revealed a suspicious soft tissue mass in one of the cases by subtraction of an overlapping pacemaker in the soft tissue image1.
Images were taken from 23 patients having at least one in-dwelling device, and the patients were all part of an on-going 600 patient study using the Reveal 35C detector at Taipei Medical University Hospital in Taiwan.
“The fact that the soft tissue image was able to find the mass, not seen in the conventional DR image, overlapping a pacemaker is quite promising and indicates that Spectral DR™ technology can efficiently subtract, in addition to bone calcium, higher atomic number materials such as metals associated with the pacemaker,” said Dr. Karim S. Karim, CTO of KA Imaging. “Spectral radiographic images generated by Spectral DR™ can play an important role in early disease detection for better outcomes,” says Amol Karnick, President and CEO.
The study will be presented at this year’s European Congress of Radiology (ECR). In addition to the e-poster at the scientific congress, KA Imaging is part of the technical exhibition at Expo X4, booth 437.
ECR is one of the largest medical meetings in Europe and the second-largest radiological meeting in the world.
Spectral DR™ technology enables dual-energy subtraction, providing bone and tissue differentiation with a single standard X-ray exposure. It acquires three images simultaneously (DR, bone and soft tissue dual-energy X-ray images). The technology mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray detectors.
About KA Imaging
A spin-off from the University of Waterloo, KA Imaging specializes in developing innovative X-ray imaging technologies and systems, providing solutions to the medical, veterinary, and non-destructive test industrial markets.
1. P-C. Chou, K. S. Karim. “Single-exposure dual-energy radiography for the subtraction of in-dwelling devices in the soft tissue image”. European Congress of Radiology-ECR 2023, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005049/en/
Contact information
Fernanda Fraga
Media Relations
ffraga@kaimaging.com
T: 226.215.9897
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Winston Taylor Completes Historic Transatlantic Combination1.6.2026 14:01:00 EEST | Press release
Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned, focused, and built for the day-to-day needs of our clients as well as their breakthrough moments.” Winston Taylor o
Kinaxis Appoints Kristin Russel as Chief Marketing Officer1.6.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives. Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment. A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partne
Samsung Electronics Begins Shipment of Industry-First HBM4E Samples1.6.2026 13:57:00 EEST | Press release
Samsung Electronics, a global leader in advanced memory technology, has begun shipping the industry's first 12-layer HBM4E samples to major global customers, further strengthening its leadership in the next-generation HBM market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601979564/en/ Samsung's 12-layer HBM4E Following the industry’s first mass production and commercial shipment of its industry-leading HBM4 earlier this year, Samsung now extends its HBM roadmap with the introduction of HBM4E samples, addressing the rapidly evolving demands of AI computing and hyperscale infrastructure. "Following the successful mass production of HBM4, Samsung has once again demonstrated its distinct technological edge with HBM4E," said Sang Joon Hwang, Executive Vice President and Head of Memory Development at Samsung Electronics. "Through our advanced manufacturing capabilities and preemptive infrastructure investments, we will con
GIGABYTE Showcases Full-Stack AI Infrastructure from Rack-Scale Systems to Real-World Deployment at COMPUTEX 20261.6.2026 13:30:00 EEST | Press release
Following the introduction of its "Future Landing" vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/ Rack-Scale Infrastructure, Validated for AI Factories At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories. Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 20261.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated BeOne pipeline assets will be presented, including: CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer. B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in advanced solid tumors. GPC3x4-1BB (BGB-B2033)bispecific antibody (rapid oral presentation): First clinical data in advanced solid tumors, including hepatocellular carcinoma (HCC), the most common type of liver cancer. Mark Lanasa, M.D., Ph.D.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom